481 research outputs found

    Results of an RF Pulsed Heating Experiment at SLAC

    Get PDF
    Results are reported from an experiment on RF pulsed heating of copper at SLAC. Damage in the form of cracks may be induced on the surface after the application of many pulses of RF. The experiment consists of two circularly cylindrical cavities operated in the TE011 mode at a resonant frequency of 11.424 GHz. Each cavity received 8.5 MW, 1.2 microsecond pulses at 60 Hz corresponding to a calculated temperature rise of 120 K on the copper surface. After 5.5 x 10^7 pulses, the experiment was stopped and the copper surfaces were examined. Damage is present on the area of the surface where the maximum heating occurred.Comment: 3 pages, 7 figures, Presented at LINAC 2000 conference, Paper ID THA1

    DIELECTRIC BRAGG ACCELERATOR

    Get PDF
    Abstract It is demonstrated that a planar Bragg reflection waveguide consisting of a series of dielectric layers may form an acceleration structure. It is shown that an interaction impedance per wavelength of over 100Ω is feasible with existing materials, Silica (ε = 2.1) and Zirconia (ε = 4), and if materials of high dielectric coefficient become available in the future, they may facilitate an interaction impedance per wavelength closer to 500Ω

    Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel

    Get PDF
    The clinical success of small-molecule vascular disrupting agents (VDAs) depends on their combination with conventional therapies. Scheduling and sequencing remain key issues in the design of VDA–chemotherapy combination treatments. This study examined the antitumour activity of ZD6126, a microtubule destabilising VDA, in combination with paclitaxel (PTX), a microtubule-stabilising cytotoxic drug, and the influence of schedule and sequence on the efficacy of the combination. Nude mice bearing MDA-MB-435 xenografts received weekly cycles of ZD6126 (200 mg kg−1 i.p.) administered at different times before or after PTX (10, 20, and 40 mg kg−1 i.v.). ZD6126 given 2 or 24 h after PTX showed no significant benefit, a result that was attributed to a protective effect of PTX against ZD6126-induced vascular damage and tumour necrosis, a hallmark of VDA activity. Paclitaxel counteracting activity was reduced by distancing drug administrations, and ZD6126 given 72 h after PTX potentiated the VDA's antitumour activity. Schedules with ZD6126 given before PTX improved therapeutic activity, which was paralleled by a VDA-induced increase in cell proliferation in the viable tumour tissue. Paclitaxel given 72 h after ZD6126 yielded the best response (50% tumours regressing). A single treatment with ZD6126 followed by weekly administration of PTX was sufficient to achieve a similar response (57% remissions). These findings show that schedule, sequence and timing are crucial in determining the antitumour efficacy of PTX in combination with ZD6126. Induction of tumour necrosis and increased proliferation in the remaining viable tumour tissue could be exploited as readouts to optimise schedules and maximise therapeutic efficacy
    • …
    corecore